

# Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care: The STRATUS Randomized Clinical Trial



**Deborah Siegal MD MSc (Pharm, Epi) FRCPC**

Associate Professor, University of Ottawa

Scientist, Ottawa Hospital Research Institute

Tier 2 Canada Research Chair in Anticoagulant Management of Cardiovascular Disease

Siegal et al. JAMA. 2023;330(19):1872-1881.doi:10.1001/jama.2023.20820



# Research question



In adult ICU patients, does the routine use of tubes that collect less blood for lab testing reduce red blood cell transfusion?

# Tubes that *automatically* collect less blood



**a.k.a short-draw or  
soft-draw or low  
vacuum**


Less vacuum = fill to  
lower volume

Same cost

Same physical  
dimensions

Same analyzers

Not used  
routinely  
in adults!



# Stepped wedge cluster randomized trial



Introduction of new policy or treatment



Intervention introduced in timed “steps”




≥1 sites receive intervention at each step



Timing of switch is randomized



Eventually all sites have intervention



# Study design and population



## ICU eligibility

Adults

Medical-surgical ICU

≥14 beds

Invasive mechanical  
ventilation

Standard-volume tubes

Electronic data available



All patients admitted to ICU




Waiver of consent



Electronic data exclusively

# Results



# Discussion


Comparison of two minimal risk standard of care interventions

Exclusively electronic data collection

Not possible without waiver of consent

Posters and letters notified patients/caregivers

Total cost of trial ~\$750,000



# The effect of **R**outine **A**utologous **P**riming on transfusion requirements after cardiac surgery (**TheRAPy**)

Jessica Spence, MD, PhD

Assistant Professor, Anesthesia and Critical Care  
Faculty of Health Sciences, McMaster University  
[jessica.spence@phri.ca](mailto:jessica.spence@phri.ca)



# Research question

Does an institutional policy of routine autologous priming decrease the mean number of units of RCCs transfused within a center up to 72 hours after cardiac surgery when compared with an institutional policy of crystalloid priming?

Pragmatic trial about clinical effectiveness, NOT efficacy.

# Study interventions

## Routine RAP policy

RAP for all patients having cardiac surgery on CPB (minimum 300mL)

Accepted avoidance of RAP in patients with a contraindication, e.g., hemodynamic instability

Expected crystalloid in  $\leq 10\%$

## Crystalloid policy

Crystalloid priming for all patients undergoing cardiac surgery on CPB

Accepted use of RAP in patients with an absolute indication for RAP, e.g., Jehovah's witness

Expected use of RAP in  $\leq 10\%$

# Study design: cluster crossover randomized trial



Hospital = cluster



Hospitals randomized instead of patients




Hospitals are randomized to use the two policies in random sequence during 12, 4-week crossover periods



All patients undergoing on-pump cardiac surgery during the study period are included

# Example randomization schedule





# Waiver of consent



Altered consent required to answer the question



Minimal risk, standard of care interventions



Lack of consent will not adversely affect participant welfare



Information provided to participants



Benefits outweigh risks of not obtaining informed consent